within Pharmacolibrary.Drugs.C_CardiovascularSystem.C09C_AngiotensinIiReceptorBlockersArbsPlain.C09CA09_AzilsartanMedoxomil;

model AzilsartanMedoxomil
  extends Pharmacolibrary.Drugs.ATC.C.C09CA09;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>C09CA09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) used primarily for the treatment of hypertension. It is an orally administered prodrug that is hydrolyzed to the active metabolite azilsartan. Azilsartan medoxomil is approved and marketed in several countries including the US and EU for blood pressure control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult male and female subjects after a single oral dose.</p><h4>References</h4><ol><li><p>Perry, CM (2012). Azilsartan medoxomil: a review of its use in hypertension. <i>Clinical drug investigation</i> 32(9) 621–639. DOI:<a href=\"https://doi.org/10.2165/11209600-000000000-00000\">10.2165/11209600-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22877322/\">https://pubmed.ncbi.nlm.nih.gov/22877322</a></p></li><li><p>Haque, E, &amp; Georg, GI (2025). Medoxomil Prodrug Strategies. <i>Journal of medicinal chemistry</i> 68(9) 9025–9036. DOI:<a href=\"https://doi.org/10.1021/acs.jmedchem.4c02967\">10.1021/acs.jmedchem.4c02967</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/40261681/\">https://pubmed.ncbi.nlm.nih.gov/40261681</a></p></li><li><p>Dudkowski, C, et al., &amp; Preston, RA (2018). Single-Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment. <i>Journal of clinical pharmacology</i> 58(1) 48–56. DOI:<a href=\"https://doi.org/10.1002/jcph.970\">10.1002/jcph.970</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28750149/\">https://pubmed.ncbi.nlm.nih.gov/28750149</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AzilsartanMedoxomil;
